As raw material and energy prices rise, so do Coloplast's costs
In Tuesday’s Q1 financial results, medtech company Coloplast’s top and bottom lines reported growth, but increasing energy expenses and wage inflation in Hungary have meant that production costs have also gone up during the first quarter.
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen
It is not only Coloplast’s top and bottom lines that have taken leaps in the first quarter of the skewed financial year 2021/2022.
Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties.